| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 78 | 2024 | 1839 | 6.750 |
Why?
|
| Soft Tissue Neoplasms | 56 | 2024 | 927 | 6.080 |
Why?
|
| Skin Neoplasms | 73 | 2024 | 4895 | 3.980 |
Why?
|
| Biomarkers, Tumor | 108 | 2024 | 10708 | 3.640 |
Why?
|
| Melanoma | 69 | 2024 | 5595 | 3.410 |
Why?
|
| Liposarcoma | 28 | 2024 | 248 | 2.800 |
Why?
|
| Bone Neoplasms | 31 | 2024 | 2665 | 2.530 |
Why?
|
| Sarcoma, Ewing | 13 | 2024 | 428 | 2.510 |
Why?
|
| Fibromatosis, Aggressive | 18 | 2024 | 110 | 2.460 |
Why?
|
| Gastrointestinal Stromal Tumors | 24 | 2024 | 318 | 2.260 |
Why?
|
| Immunohistochemistry | 81 | 2024 | 7655 | 1.900 |
Why?
|
| Hemangiosarcoma | 12 | 2022 | 238 | 1.900 |
Why?
|
| Leiomyosarcoma | 15 | 2024 | 253 | 1.810 |
Why?
|
| Nerve Sheath Neoplasms | 15 | 2024 | 82 | 1.740 |
Why?
|
| Oncogene Proteins, Fusion | 25 | 2024 | 797 | 1.720 |
Why?
|
| Retroperitoneal Neoplasms | 10 | 2024 | 296 | 1.630 |
Why?
|
| Humans | 456 | 2024 | 270740 | 1.550 |
Why?
|
| Sebaceous Gland Neoplasms | 7 | 2012 | 100 | 1.510 |
Why?
|
| Sarcoma, Small Cell | 2 | 2024 | 6 | 1.500 |
Why?
|
| Osteosarcoma | 14 | 2024 | 950 | 1.490 |
Why?
|
| Neoplasms | 46 | 2024 | 15927 | 1.460 |
Why?
|
| Tissue Array Analysis | 31 | 2020 | 757 | 1.320 |
Why?
|
| World Health Organization | 8 | 2024 | 327 | 1.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 49 | 2024 | 9042 | 1.230 |
Why?
|
| RNA-Binding Protein EWS | 9 | 2024 | 106 | 1.230 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2022 | 38 | 1.200 |
Why?
|
| beta Catenin | 17 | 2023 | 683 | 1.190 |
Why?
|
| Mutation | 72 | 2024 | 15912 | 1.180 |
Why?
|
| Sarcoma, Synovial | 9 | 2024 | 141 | 1.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 20 | 2024 | 1336 | 1.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 20 | 2024 | 2359 | 1.150 |
Why?
|
| Uterine Neoplasms | 10 | 2021 | 576 | 1.130 |
Why?
|
| Sarcoma, Alveolar Soft Part | 5 | 2022 | 74 | 1.100 |
Why?
|
| Adenocarcinoma, Sebaceous | 3 | 2012 | 66 | 1.040 |
Why?
|
| Muir-Torre Syndrome | 4 | 2019 | 18 | 1.040 |
Why?
|
| Adult | 168 | 2024 | 82040 | 1.030 |
Why?
|
| Proteogenomics | 5 | 2024 | 110 | 1.020 |
Why?
|
| Gene Fusion | 10 | 2022 | 214 | 1.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 14 | 2018 | 484 | 1.010 |
Why?
|
| Fibrosarcoma | 6 | 2024 | 143 | 0.990 |
Why?
|
| PAX7 Transcription Factor | 4 | 2018 | 22 | 0.980 |
Why?
|
| Aged | 149 | 2024 | 73333 | 0.970 |
Why?
|
| Female | 217 | 2024 | 148940 | 0.970 |
Why?
|
| Male | 192 | 2024 | 128315 | 0.960 |
Why?
|
| Tumor Suppressor Protein p53 | 24 | 2024 | 3658 | 0.960 |
Why?
|
| Genomics | 16 | 2024 | 2835 | 0.940 |
Why?
|
| Prognosis | 78 | 2024 | 22505 | 0.930 |
Why?
|
| Middle Aged | 167 | 2024 | 90352 | 0.920 |
Why?
|
| PTEN Phosphohydrolase | 9 | 2023 | 1012 | 0.910 |
Why?
|
| Trans-Activators | 9 | 2019 | 1624 | 0.900 |
Why?
|
| Neoplasm Recurrence, Local | 43 | 2024 | 10400 | 0.890 |
Why?
|
| Neurofibromatosis 1 | 7 | 2024 | 159 | 0.890 |
Why?
|
| Nevus | 4 | 2024 | 116 | 0.870 |
Why?
|
| Solitary Fibrous Tumors | 6 | 2024 | 48 | 0.850 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2022 | 5 | 0.830 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2022 | 20 | 0.810 |
Why?
|
| Transcriptome | 11 | 2024 | 1963 | 0.810 |
Why?
|
| Head and Neck Neoplasms | 9 | 2022 | 4147 | 0.780 |
Why?
|
| Young Adult | 74 | 2024 | 22251 | 0.780 |
Why?
|
| Translocation, Genetic | 14 | 2024 | 1286 | 0.770 |
Why?
|
| DNA Mutational Analysis | 19 | 2021 | 2357 | 0.760 |
Why?
|
| Melanocytes | 3 | 2021 | 240 | 0.750 |
Why?
|
| Neurilemmoma | 8 | 2024 | 134 | 0.750 |
Why?
|
| Cell Line, Tumor | 59 | 2024 | 14849 | 0.750 |
Why?
|
| Pathology, Molecular | 3 | 2019 | 124 | 0.720 |
Why?
|
| Aged, 80 and over | 80 | 2024 | 30998 | 0.720 |
Why?
|
| Nevus, Pigmented | 4 | 2019 | 116 | 0.720 |
Why?
|
| Signal Transduction | 35 | 2021 | 12103 | 0.710 |
Why?
|
| DNA Methylation | 11 | 2024 | 2765 | 0.710 |
Why?
|
| In Situ Hybridization, Fluorescence | 23 | 2023 | 2313 | 0.710 |
Why?
|
| Molecular Targeted Therapy | 14 | 2022 | 2399 | 0.710 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 232 | 0.680 |
Why?
|
| Gene Expression Profiling | 22 | 2024 | 5149 | 0.670 |
Why?
|
| Antineoplastic Agents | 33 | 2024 | 14617 | 0.660 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2024 | 625 | 0.650 |
Why?
|
| Repressor Proteins | 9 | 2024 | 1718 | 0.650 |
Why?
|
| Polycomb Repressive Complex 2 | 5 | 2024 | 162 | 0.630 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2023 | 1032 | 0.610 |
Why?
|
| Adolescent | 76 | 2024 | 32767 | 0.610 |
Why?
|
| Uveal Neoplasms | 5 | 2022 | 194 | 0.610 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2022 | 1710 | 0.600 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 425 | 0.590 |
Why?
|
| Pathology, Clinical | 8 | 2021 | 129 | 0.580 |
Why?
|
| Monophenol Monooxygenase | 1 | 2017 | 60 | 0.580 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 213 | 0.570 |
Why?
|
| Endometrial Neoplasms | 6 | 2024 | 1385 | 0.570 |
Why?
|
| Diagnosis, Differential | 23 | 2024 | 4831 | 0.570 |
Why?
|
| Skin Diseases | 5 | 2021 | 366 | 0.570 |
Why?
|
| DNA Copy Number Variations | 16 | 2024 | 1568 | 0.570 |
Why?
|
| Transcription Factors | 20 | 2024 | 5438 | 0.560 |
Why?
|
| Pathology | 2 | 2018 | 102 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-akt | 13 | 2023 | 2069 | 0.550 |
Why?
|
| Histones | 8 | 2024 | 1513 | 0.550 |
Why?
|
| Gene Rearrangement | 9 | 2024 | 813 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2023 | 4961 | 0.550 |
Why?
|
| Liposarcoma, Myxoid | 5 | 2022 | 38 | 0.550 |
Why?
|
| Gene Amplification | 6 | 2023 | 766 | 0.550 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 15 | 0.540 |
Why?
|
| Chromosomal Instability | 2 | 2018 | 229 | 0.540 |
Why?
|
| Immunotherapy | 16 | 2023 | 3557 | 0.540 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2024 | 2617 | 0.540 |
Why?
|
| Telomerase | 4 | 2023 | 547 | 0.530 |
Why?
|
| Neoplasm Metastasis | 25 | 2021 | 5315 | 0.530 |
Why?
|
| Programmed Cell Death 1 Receptor | 9 | 2021 | 1097 | 0.520 |
Why?
|
| Laboratory Proficiency Testing | 4 | 2019 | 17 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 9 | 2024 | 1586 | 0.510 |
Why?
|
| Extremities | 6 | 2022 | 311 | 0.510 |
Why?
|
| Neoplasm Proteins | 10 | 2020 | 3345 | 0.510 |
Why?
|
| Predictive Value of Tests | 16 | 2024 | 4960 | 0.510 |
Why?
|
| Disease-Free Survival | 29 | 2019 | 10265 | 0.500 |
Why?
|
| TOR Serine-Threonine Kinases | 10 | 2022 | 1563 | 0.500 |
Why?
|
| Standard of Care | 2 | 2018 | 277 | 0.500 |
Why?
|
| Dermatofibrosarcoma | 6 | 2012 | 73 | 0.500 |
Why?
|
| Survival Rate | 41 | 2024 | 12541 | 0.500 |
Why?
|
| Mice | 63 | 2024 | 35600 | 0.490 |
Why?
|
| Muscle, Smooth | 2 | 2017 | 251 | 0.490 |
Why?
|
| Valine | 2 | 2015 | 180 | 0.490 |
Why?
|
| Oncogene Fusion | 5 | 2018 | 62 | 0.490 |
Why?
|
| Glomus Tumor | 2 | 2023 | 29 | 0.490 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2015 | 114 | 0.490 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2022 | 980 | 0.480 |
Why?
|
| Histiocytoma, Malignant Fibrous | 5 | 2020 | 49 | 0.470 |
Why?
|
| Cell Proliferation | 29 | 2021 | 7238 | 0.470 |
Why?
|
| Adenoma | 3 | 2010 | 740 | 0.470 |
Why?
|
| Chromatin | 5 | 2024 | 1046 | 0.460 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 101 | 0.460 |
Why?
|
| Autophagy | 7 | 2019 | 911 | 0.460 |
Why?
|
| Abdominal Neoplasms | 5 | 2015 | 251 | 0.460 |
Why?
|
| Membrane Proteins | 11 | 2021 | 2928 | 0.460 |
Why?
|
| Databases, Genetic | 10 | 2018 | 757 | 0.450 |
Why?
|
| Colitis | 3 | 2022 | 341 | 0.450 |
Why?
|
| Animals | 75 | 2024 | 61956 | 0.450 |
Why?
|
| Adaptor Proteins, Signal Transducing | 10 | 2022 | 1470 | 0.450 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 4 | 2010 | 65 | 0.450 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2020 | 402 | 0.440 |
Why?
|
| Enzyme Inhibitors | 4 | 2017 | 1942 | 0.440 |
Why?
|
| Sweat Gland Neoplasms | 3 | 2012 | 72 | 0.440 |
Why?
|
| Piperazines | 14 | 2022 | 2145 | 0.440 |
Why?
|
| Neoplasm Staging | 33 | 2022 | 14012 | 0.440 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 4958 | 0.440 |
Why?
|
| Lipoma | 2 | 2013 | 93 | 0.440 |
Why?
|
| Sarcoma, Clear Cell | 4 | 2021 | 43 | 0.440 |
Why?
|
| Child | 53 | 2024 | 30559 | 0.430 |
Why?
|
| Neoplasm Grading | 9 | 2024 | 1823 | 0.430 |
Why?
|
| Precision Medicine | 3 | 2017 | 1207 | 0.420 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 2 | 2024 | 47 | 0.420 |
Why?
|
| Fibroma | 1 | 2013 | 86 | 0.410 |
Why?
|
| Pilomatrixoma | 3 | 2011 | 9 | 0.410 |
Why?
|
| Retrospective Studies | 49 | 2024 | 39890 | 0.410 |
Why?
|
| Cytoskeletal Proteins | 2 | 2005 | 522 | 0.410 |
Why?
|
| Endothelial Cells | 3 | 2019 | 1038 | 0.400 |
Why?
|
| ErbB Receptors | 9 | 2019 | 2375 | 0.400 |
Why?
|
| Glycoside Hydrolases | 1 | 2012 | 42 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 17 | 2019 | 4048 | 0.400 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 3035 | 0.400 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 2 | 2023 | 17 | 0.400 |
Why?
|
| Combined Modality Therapy | 23 | 2024 | 9039 | 0.390 |
Why?
|
| Lymphatic Metastasis | 16 | 2018 | 4963 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2023 | 5408 | 0.390 |
Why?
|
| SMARCB1 Protein | 5 | 2019 | 107 | 0.390 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2022 | 103 | 0.380 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2012 | 304 | 0.380 |
Why?
|
| Carcinogenesis | 5 | 2018 | 1033 | 0.380 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2015 | 226 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 3 | 2023 | 1388 | 0.380 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2012 | 334 | 0.380 |
Why?
|
| Cell Dedifferentiation | 4 | 2018 | 100 | 0.380 |
Why?
|
| Cell Differentiation | 13 | 2021 | 4116 | 0.380 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 627 | 0.380 |
Why?
|
| Hair Diseases | 4 | 2022 | 42 | 0.370 |
Why?
|
| MicroRNAs | 9 | 2022 | 2887 | 0.370 |
Why?
|
| Pyrimidines | 17 | 2024 | 3669 | 0.370 |
Why?
|
| Carcinoma | 6 | 2022 | 2610 | 0.370 |
Why?
|
| Dermatology | 3 | 2021 | 72 | 0.360 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2012 | 694 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 11 | 2024 | 5231 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 20 | 2024 | 3917 | 0.360 |
Why?
|
| Anus Neoplasms | 2 | 2019 | 414 | 0.360 |
Why?
|
| S100 Proteins | 3 | 2023 | 186 | 0.350 |
Why?
|
| CTLA-4 Antigen | 6 | 2021 | 678 | 0.350 |
Why?
|
| Cohort Studies | 23 | 2021 | 9470 | 0.350 |
Why?
|
| DNA-Binding Proteins | 10 | 2024 | 5002 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2021 | 6256 | 0.350 |
Why?
|
| Receptor, IGF Type 1 | 6 | 2020 | 350 | 0.350 |
Why?
|
| Proteomics | 7 | 2024 | 1427 | 0.340 |
Why?
|
| GTP Phosphohydrolases | 4 | 2021 | 339 | 0.340 |
Why?
|
| Tertiary Lymphoid Structures | 2 | 2020 | 37 | 0.340 |
Why?
|
| Neurofibrosarcoma | 4 | 2024 | 42 | 0.340 |
Why?
|
| DNA, Neoplasm | 10 | 2018 | 1958 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2023 | 2453 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 15 | 2015 | 3597 | 0.330 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 2 | 2022 | 88 | 0.330 |
Why?
|
| Esophageal and Gastric Varices | 4 | 1998 | 93 | 0.330 |
Why?
|
| Subcutaneous Tissue | 1 | 2009 | 57 | 0.330 |
Why?
|
| Treatment Outcome | 40 | 2024 | 33737 | 0.330 |
Why?
|
| Biopsy | 13 | 2021 | 3484 | 0.320 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2021 | 72 | 0.320 |
Why?
|
| Mesenchymoma | 2 | 2009 | 14 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2022 | 3409 | 0.320 |
Why?
|
| Epigenesis, Genetic | 8 | 2024 | 1441 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2024 | 5776 | 0.320 |
Why?
|
| Benzenesulfonates | 2 | 2012 | 196 | 0.320 |
Why?
|
| Adenocarcinoma | 8 | 2021 | 7914 | 0.320 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2008 | 290 | 0.310 |
Why?
|
| Mice, SCID | 15 | 2017 | 1826 | 0.310 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2017 | 225 | 0.310 |
Why?
|
| Epithelioid Cells | 4 | 2012 | 45 | 0.310 |
Why?
|
| Skin Transplantation | 2 | 2009 | 186 | 0.310 |
Why?
|
| Receptors, Somatomedin | 3 | 2017 | 72 | 0.300 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2015 | 334 | 0.300 |
Why?
|
| Follow-Up Studies | 25 | 2024 | 15218 | 0.300 |
Why?
|
| Child, Preschool | 27 | 2024 | 17061 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2023 | 382 | 0.300 |
Why?
|
| Antigens, CD34 | 5 | 2013 | 640 | 0.300 |
Why?
|
| Sclerosis | 3 | 2019 | 76 | 0.290 |
Why?
|
| Phenotype | 11 | 2024 | 6509 | 0.290 |
Why?
|
| Torso | 2 | 2020 | 74 | 0.290 |
Why?
|
| Cell Nucleus | 10 | 2018 | 1712 | 0.290 |
Why?
|
| Myofibroma | 2 | 2017 | 12 | 0.290 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 1435 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2024 | 1281 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2024 | 2386 | 0.290 |
Why?
|
| Cell Movement | 13 | 2017 | 2472 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2024 | 16689 | 0.280 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2007 | 12 | 0.280 |
Why?
|
| Single-Cell Analysis | 4 | 2024 | 557 | 0.280 |
Why?
|
| Apoptosis | 17 | 2021 | 7757 | 0.280 |
Why?
|
| Fasciitis | 2 | 2017 | 39 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2018 | 426 | 0.280 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 617 | 0.280 |
Why?
|
| Rhabdomyosarcoma | 2 | 2023 | 342 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2018 | 1903 | 0.280 |
Why?
|
| MAP Kinase Signaling System | 4 | 2021 | 885 | 0.280 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2017 | 155 | 0.280 |
Why?
|
| Receptors, Androgen | 2 | 2022 | 854 | 0.280 |
Why?
|
| Intestinal Mucosa | 6 | 2023 | 1105 | 0.280 |
Why?
|
| B7-H1 Antigen | 5 | 2020 | 1089 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2015 | 678 | 0.270 |
Why?
|
| Myxoma | 2 | 2020 | 67 | 0.270 |
Why?
|
| Mouth Neoplasms | 2 | 2014 | 734 | 0.270 |
Why?
|
| Clone Cells | 3 | 2023 | 591 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 5 | 2015 | 525 | 0.260 |
Why?
|
| Pyrimidinones | 4 | 2021 | 318 | 0.260 |
Why?
|
| Facial Neoplasms | 1 | 2006 | 77 | 0.260 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 227 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2018 | 5593 | 0.260 |
Why?
|
| Pyridines | 5 | 2022 | 1313 | 0.260 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 1424 | 0.260 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2018 | 206 | 0.250 |
Why?
|
| Granular Cell Tumor | 1 | 2005 | 22 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 585 | 0.250 |
Why?
|
| Imidazoles | 6 | 2018 | 1065 | 0.250 |
Why?
|
| Genes, ras | 4 | 2018 | 679 | 0.250 |
Why?
|
| Benzamides | 12 | 2017 | 1879 | 0.250 |
Why?
|
| Oncogenes | 4 | 2023 | 699 | 0.250 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2019 | 368 | 0.250 |
Why?
|
| Ipilimumab | 3 | 2018 | 764 | 0.250 |
Why?
|
| Paraffin Embedding | 4 | 2018 | 223 | 0.250 |
Why?
|
| Nail Diseases | 1 | 2005 | 39 | 0.250 |
Why?
|
| Receptor, trkA | 2 | 2022 | 40 | 0.240 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2023 | 66 | 0.240 |
Why?
|
| Observer Variation | 2 | 2024 | 709 | 0.240 |
Why?
|
| Circulating Tumor DNA | 2 | 2018 | 274 | 0.240 |
Why?
|
| Ribonuclease H | 1 | 2024 | 18 | 0.240 |
Why?
|
| beta Karyopherins | 2 | 2015 | 34 | 0.240 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2024 | 63 | 0.240 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2024 | 38 | 0.240 |
Why?
|
| Smooth Muscle Tumor | 2 | 2024 | 15 | 0.240 |
Why?
|
| Kidney Neoplasms | 5 | 2024 | 3108 | 0.240 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 4 | 2013 | 168 | 0.240 |
Why?
|
| Dermis | 1 | 2004 | 63 | 0.240 |
Why?
|
| Levonorgestrel | 1 | 2024 | 53 | 0.230 |
Why?
|
| Epithelial-Mesenchymal Transition | 6 | 2018 | 1002 | 0.230 |
Why?
|
| Survival Analysis | 13 | 2022 | 9292 | 0.230 |
Why?
|
| Heme | 1 | 2024 | 83 | 0.230 |
Why?
|
| CpG Islands | 2 | 2024 | 671 | 0.230 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2023 | 76 | 0.230 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2024 | 12 | 0.230 |
Why?
|
| Blotting, Western | 11 | 2015 | 3584 | 0.230 |
Why?
|
| Disease Progression | 13 | 2018 | 6867 | 0.230 |
Why?
|
| Fecal Microbiota Transplantation | 3 | 2021 | 168 | 0.230 |
Why?
|
| Receptors, Fc | 1 | 2024 | 72 | 0.230 |
Why?
|
| Genome, Human | 4 | 2021 | 1888 | 0.230 |
Why?
|
| T-Lymphocytes | 7 | 2021 | 3949 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 366 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2007 | 442 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 6 | 2024 | 3216 | 0.220 |
Why?
|
| Time Factors | 14 | 2024 | 13006 | 0.220 |
Why?
|
| Indoles | 3 | 2015 | 1028 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 3 | 2023 | 676 | 0.220 |
Why?
|
| Endometrial Hyperplasia | 1 | 2024 | 122 | 0.220 |
Why?
|
| Receptors, Notch | 2 | 2017 | 372 | 0.220 |
Why?
|
| Genes, p53 | 6 | 2021 | 1140 | 0.220 |
Why?
|
| Tumor Burden | 10 | 2021 | 2033 | 0.220 |
Why?
|
| Reproducibility of Results | 12 | 2024 | 6177 | 0.220 |
Why?
|
| Tomography, Optical Coherence | 3 | 2014 | 550 | 0.220 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2015 | 40 | 0.220 |
Why?
|
| Phosphorylation | 9 | 2023 | 4942 | 0.210 |
Why?
|
| Sclerotherapy | 2 | 1994 | 53 | 0.210 |
Why?
|
| Fingers | 3 | 2022 | 130 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2019 | 1402 | 0.210 |
Why?
|
| Introns | 1 | 2024 | 461 | 0.210 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2022 | 14 | 0.210 |
Why?
|
| Retinoblastoma | 2 | 2023 | 189 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2022 | 1335 | 0.210 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 25 | 0.210 |
Why?
|
| Scleroderma, Localized | 1 | 2012 | 13 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2020 | 659 | 0.210 |
Why?
|
| Terminology as Topic | 3 | 2021 | 418 | 0.210 |
Why?
|
| Vascular Neoplasms | 2 | 2016 | 112 | 0.210 |
Why?
|
| Aneuploidy | 3 | 2018 | 382 | 0.210 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 809 | 0.210 |
Why?
|
| RNA-Binding Protein FUS | 2 | 2012 | 25 | 0.200 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 34 | 0.200 |
Why?
|
| B7 Antigens | 2 | 2022 | 84 | 0.200 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2019 | 172 | 0.200 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 116 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 8 | 2016 | 1189 | 0.200 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 437 | 0.200 |
Why?
|
| Colitis, Ulcerative | 2 | 2015 | 258 | 0.200 |
Why?
|
| Exons | 6 | 2015 | 1383 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 1051 | 0.200 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 1034 | 0.190 |
Why?
|
| United States | 16 | 2021 | 15861 | 0.190 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2021 | 491 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 451 | 0.190 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2021 | 42 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2017 | 1367 | 0.190 |
Why?
|
| Pyridones | 3 | 2021 | 360 | 0.190 |
Why?
|
| Phyllodes Tumor | 1 | 2022 | 64 | 0.190 |
Why?
|
| Infant | 17 | 2021 | 13999 | 0.190 |
Why?
|
| Retinal Neoplasms | 1 | 2023 | 137 | 0.190 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2024 | 241 | 0.190 |
Why?
|
| Phosphoglycerate Dehydrogenase | 1 | 2021 | 9 | 0.190 |
Why?
|
| Radiotherapy | 6 | 2019 | 1857 | 0.190 |
Why?
|
| Iron | 1 | 2024 | 380 | 0.190 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2022 | 262 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 127 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2012 | 77 | 0.190 |
Why?
|
| Pathologists | 4 | 2024 | 101 | 0.190 |
Why?
|
| Vimentin | 3 | 2010 | 252 | 0.190 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 1340 | 0.180 |
Why?
|
| Tropomyosin | 1 | 2020 | 39 | 0.180 |
Why?
|
| DNA Repair | 4 | 2024 | 1909 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 4481 | 0.180 |
Why?
|
| Models, Biological | 4 | 2019 | 3194 | 0.180 |
Why?
|
| Acetylation | 2 | 2023 | 515 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2017 | 507 | 0.180 |
Why?
|
| Imatinib Mesylate | 11 | 2018 | 1691 | 0.180 |
Why?
|
| RNA, Small Interfering | 8 | 2015 | 2196 | 0.180 |
Why?
|
| Breast Neoplasms | 8 | 2024 | 16215 | 0.180 |
Why?
|
| Chordoma | 1 | 2022 | 170 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2021 | 557 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2021 | 234 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2020 | 69 | 0.180 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2020 | 21 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2018 | 529 | 0.180 |
Why?
|
| Calmodulin-Binding Proteins | 3 | 2009 | 91 | 0.180 |
Why?
|
| Collagen Type I | 2 | 2012 | 187 | 0.180 |
Why?
|
| Formaldehyde | 2 | 2018 | 116 | 0.180 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 79 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2017 | 2471 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.170 |
Why?
|
| Chromosomal Proteins, Non-Histone | 4 | 2015 | 376 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 9 | 2023 | 5759 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2021 | 329 | 0.170 |
Why?
|
| Amino Acid Substitution | 3 | 2013 | 657 | 0.170 |
Why?
|
| RNA, Neoplasm | 2 | 2021 | 805 | 0.170 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2012 | 258 | 0.170 |
Why?
|
| Germ Cells | 2 | 2021 | 329 | 0.170 |
Why?
|
| Homeodomain Proteins | 2 | 2022 | 1125 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2019 | 2271 | 0.170 |
Why?
|
| Liver Neoplasms | 5 | 2022 | 4821 | 0.170 |
Why?
|
| Hafnium | 1 | 2019 | 1 | 0.170 |
Why?
|
| RNA, Messenger | 9 | 2018 | 6390 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 266 | 0.170 |
Why?
|
| Sentinel Lymph Node | 1 | 2022 | 235 | 0.170 |
Why?
|
| Cytodiagnosis | 1 | 2020 | 201 | 0.170 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 30 | 0.170 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2011 | 99 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 274 | 0.170 |
Why?
|
| Prospective Studies | 13 | 2024 | 13414 | 0.170 |
Why?
|
| Transfection | 6 | 2020 | 3117 | 0.170 |
Why?
|
| Oximes | 2 | 2018 | 191 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 481 | 0.170 |
Why?
|
| NF-kappa B | 3 | 2012 | 1563 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 3476 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2023 | 875 | 0.170 |
Why?
|
| Metformin | 1 | 2023 | 393 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 4 | 2015 | 545 | 0.170 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 316 | 0.170 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 341 | 0.160 |
Why?
|
| Wound Healing | 3 | 2018 | 749 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2015 | 520 | 0.160 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2019 | 68 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 7 | 2018 | 1076 | 0.160 |
Why?
|
| Machine Learning | 2 | 2023 | 360 | 0.160 |
Why?
|
| Blood Cell Count | 1 | 1999 | 233 | 0.160 |
Why?
|
| Bone and Bones | 2 | 2023 | 605 | 0.160 |
Why?
|
| Methylation | 1 | 2020 | 625 | 0.160 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2019 | 87 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 241 | 0.160 |
Why?
|
| Quinazolines | 4 | 2021 | 956 | 0.160 |
Why?
|
| Adalimumab | 2 | 2015 | 48 | 0.160 |
Why?
|
| Medical Oncology | 5 | 2019 | 1465 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 204 | 0.160 |
Why?
|
| Adenosarcoma | 1 | 2018 | 16 | 0.160 |
Why?
|
| Karyotyping | 4 | 2009 | 1063 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 6 | 2021 | 2573 | 0.160 |
Why?
|
| Oxides | 1 | 2019 | 212 | 0.160 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 5101 | 0.160 |
Why?
|
| Proteostasis | 1 | 2019 | 50 | 0.160 |
Why?
|
| Carcinosarcoma | 2 | 2018 | 145 | 0.150 |
Why?
|
| RNA Splicing | 1 | 2020 | 361 | 0.150 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2018 | 16 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2021 | 2250 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 33 | 0.150 |
Why?
|
| Liver Cirrhosis | 3 | 1998 | 1046 | 0.150 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 106 | 0.150 |
Why?
|
| DNA Mismatch Repair | 2 | 2012 | 283 | 0.150 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 58 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2018 | 477 | 0.150 |
Why?
|
| Laboratories | 1 | 2019 | 132 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1655 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2018 | 51 | 0.150 |
Why?
|
| Antigens, Neoplasm | 4 | 2014 | 1580 | 0.150 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 117 | 0.150 |
Why?
|
| Lung Neoplasms | 10 | 2021 | 12033 | 0.150 |
Why?
|
| X-linked Nuclear Protein | 1 | 2017 | 54 | 0.150 |
Why?
|
| Diphenylamine | 1 | 2017 | 16 | 0.150 |
Why?
|
| Up-Regulation | 7 | 2020 | 2422 | 0.150 |
Why?
|
| Dacarbazine | 2 | 2011 | 502 | 0.150 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 164 | 0.150 |
Why?
|
| Eyelid Neoplasms | 2 | 2011 | 193 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 135 | 0.150 |
Why?
|
| Doxorubicin | 3 | 2017 | 3145 | 0.150 |
Why?
|
| Heterografts | 5 | 2024 | 738 | 0.150 |
Why?
|
| Risk Assessment | 9 | 2020 | 6764 | 0.140 |
Why?
|
| Manometry | 1 | 2017 | 72 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 460 | 0.140 |
Why?
|
| Cartilage | 1 | 2017 | 110 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 203 | 0.140 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 97 | 0.140 |
Why?
|
| Morpholines | 3 | 2015 | 296 | 0.140 |
Why?
|
| Antigens, CD | 3 | 2013 | 1418 | 0.140 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2019 | 510 | 0.140 |
Why?
|
| RNA-Binding Proteins | 4 | 2018 | 1017 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 4328 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 2 | 2008 | 36 | 0.140 |
Why?
|
| Mice, Nude | 7 | 2021 | 4329 | 0.140 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 680 | 0.140 |
Why?
|
| Cell Lineage | 2 | 2021 | 701 | 0.140 |
Why?
|
| Biomarkers | 7 | 2023 | 5051 | 0.140 |
Why?
|
| Recurrence | 7 | 2018 | 4878 | 0.140 |
Why?
|
| Thyrotropin | 1 | 2017 | 124 | 0.140 |
Why?
|
| Sulfonamides | 3 | 2024 | 1933 | 0.140 |
Why?
|
| Clonal Evolution | 2 | 2018 | 250 | 0.140 |
Why?
|
| Telomere | 2 | 2013 | 550 | 0.140 |
Why?
|
| Sirolimus | 5 | 2016 | 831 | 0.140 |
Why?
|
| Mucin-1 | 2 | 2007 | 158 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 131 | 0.140 |
Why?
|
| Pharynx | 1 | 2017 | 150 | 0.140 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1418 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 3438 | 0.140 |
Why?
|
| Leukapheresis | 2 | 1999 | 166 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 7100 | 0.140 |
Why?
|
| Ifosfamide | 1 | 2017 | 358 | 0.140 |
Why?
|
| Carrier Proteins | 3 | 2020 | 2098 | 0.140 |
Why?
|
| Societies, Medical | 6 | 2021 | 1320 | 0.140 |
Why?
|
| Cell Cycle | 8 | 2018 | 2137 | 0.140 |
Why?
|
| RNA Interference | 4 | 2015 | 1388 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 416 | 0.130 |
Why?
|
| Wnt Proteins | 4 | 2018 | 384 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 7895 | 0.130 |
Why?
|
| Computational Biology | 3 | 2018 | 1291 | 0.130 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 2 | 2013 | 50 | 0.130 |
Why?
|
| Neurofibroma | 3 | 2024 | 31 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2014 | 1838 | 0.130 |
Why?
|
| American Cancer Society | 1 | 2016 | 35 | 0.130 |
Why?
|
| Pneumonia | 1 | 2022 | 796 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 571 | 0.130 |
Why?
|
| Risk Factors | 12 | 2024 | 17888 | 0.130 |
Why?
|
| Chromones | 2 | 2015 | 121 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2021 | 2166 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 2016 | 167 | 0.130 |
Why?
|
| Gene Expression | 3 | 2019 | 3640 | 0.130 |
Why?
|
| Base Sequence | 7 | 2012 | 5437 | 0.130 |
Why?
|
| Hypertension, Portal | 2 | 1994 | 129 | 0.130 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1995 | 6 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 359 | 0.130 |
Why?
|
| Spiro Compounds | 1 | 2015 | 59 | 0.130 |
Why?
|
| Skin | 4 | 2010 | 1271 | 0.130 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 2810 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2018 | 337 | 0.130 |
Why?
|
| Cofilin 2 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Protein Kinase C | 1 | 2017 | 407 | 0.130 |
Why?
|
| Leptin | 1 | 2017 | 306 | 0.120 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 85 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2024 | 1389 | 0.120 |
Why?
|
| Cytogenetic Analysis | 4 | 2011 | 574 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 530 | 0.120 |
Why?
|
| Desmin | 1 | 2015 | 61 | 0.120 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 675 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2013 | 198 | 0.120 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 39 | 0.120 |
Why?
|
| Adipocytes | 2 | 2015 | 299 | 0.120 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1999 | 662 | 0.120 |
Why?
|
| Pyrroles | 3 | 2017 | 588 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 68 | 0.120 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 50 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2017 | 427 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 295 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 2486 | 0.120 |
Why?
|
| Heterochromatin | 1 | 2015 | 90 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2017 | 648 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 69 | 0.120 |
Why?
|
| Lymphoma | 3 | 2022 | 1519 | 0.120 |
Why?
|
| Mesoderm | 2 | 2021 | 392 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 551 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2013 | 202 | 0.120 |
Why?
|
| Rectum | 2 | 2015 | 480 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 255 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2015 | 322 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 522 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 2454 | 0.120 |
Why?
|
| Australia | 3 | 2023 | 259 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 585 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 3339 | 0.120 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 2035 | 0.120 |
Why?
|
| Hemostasis, Endoscopic | 1 | 1994 | 34 | 0.120 |
Why?
|
| Germ-Line Mutation | 3 | 2018 | 1101 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 2 | 2008 | 572 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 1059 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2012 | 69 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 631 | 0.110 |
Why?
|
| Postoperative Complications | 6 | 2017 | 5681 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2019 | 506 | 0.110 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 7381 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 878 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 201 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2010 | 126 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 593 | 0.110 |
Why?
|
| Phthalazines | 1 | 2015 | 262 | 0.110 |
Why?
|
| Gonanes | 1 | 2013 | 50 | 0.110 |
Why?
|
| Cytokines | 3 | 2017 | 2825 | 0.110 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 1379 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2022 | 1050 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1485 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 277 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2016 | 501 | 0.110 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 5162 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2017 | 1136 | 0.110 |
Why?
|
| Membrane Glycoproteins | 3 | 2024 | 1094 | 0.110 |
Why?
|
| Biological Products | 1 | 2017 | 319 | 0.110 |
Why?
|
| Cluster Analysis | 3 | 2024 | 1075 | 0.110 |
Why?
|
| Factor VIII | 1 | 2013 | 65 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 537 | 0.110 |
Why?
|
| Down-Regulation | 5 | 2019 | 2090 | 0.110 |
Why?
|
| Inflammation | 3 | 2012 | 2518 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 111 | 0.110 |
Why?
|
| Vincristine | 1 | 2017 | 1583 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 179 | 0.110 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 489 | 0.110 |
Why?
|
| Mucin-4 | 1 | 2012 | 17 | 0.110 |
Why?
|
| Toes | 1 | 2012 | 48 | 0.110 |
Why?
|
| bcl-Associated Death Protein | 1 | 2012 | 24 | 0.110 |
Why?
|
| Autocrine Communication | 1 | 2013 | 88 | 0.100 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 77 | 0.100 |
Why?
|
| Physical Stimulation | 1 | 2012 | 116 | 0.100 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 382 | 0.100 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 2062 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1584 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 131 | 0.100 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2012 | 5 | 0.100 |
Why?
|
| Antibodies | 1 | 2015 | 809 | 0.100 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 48 | 0.100 |
Why?
|
| Thiocarbamates | 1 | 2012 | 18 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2012 | 18 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2018 | 749 | 0.100 |
Why?
|
| Casein Kinase I | 1 | 2012 | 22 | 0.100 |
Why?
|
| Keratins | 1 | 2013 | 340 | 0.100 |
Why?
|
| Splenorenal Shunt, Surgical | 1 | 1991 | 1 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2013 | 307 | 0.100 |
Why?
|
| Cell Survival | 6 | 2015 | 3063 | 0.100 |
Why?
|
| Genes, APC | 1 | 2012 | 71 | 0.100 |
Why?
|
| Drug Synergism | 5 | 2016 | 1356 | 0.100 |
Why?
|
| Mice, Knockout | 6 | 2019 | 5728 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 201 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2014 | 715 | 0.100 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 134 | 0.100 |
Why?
|
| Vascular Malformations | 1 | 2013 | 88 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 444 | 0.100 |
Why?
|
| Drug Delivery Systems | 3 | 2010 | 661 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 217 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 561 | 0.100 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2011 | 9 | 0.100 |
Why?
|
| Pyrrolidines | 1 | 2012 | 113 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2012 | 97 | 0.100 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2012 | 57 | 0.100 |
Why?
|
| Microsatellite Instability | 3 | 2018 | 408 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 210 | 0.100 |
Why?
|
| Pleural Neoplasms | 2 | 2016 | 485 | 0.100 |
Why?
|
| Transfusion Reaction | 1 | 1992 | 101 | 0.100 |
Why?
|
| Lentivirus | 1 | 2012 | 164 | 0.100 |
Why?
|
| Paraganglioma | 1 | 2014 | 200 | 0.100 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 162 | 0.100 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 654 | 0.100 |
Why?
|
| Hemangioma | 1 | 2013 | 157 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1739 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 128 | 0.100 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2011 | 64 | 0.090 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 271 | 0.090 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 3 | 2021 | 264 | 0.090 |
Why?
|
| Integrin alphaV | 1 | 2011 | 24 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 248 | 0.090 |
Why?
|
| fas Receptor | 1 | 2012 | 197 | 0.090 |
Why?
|
| Cyclin D1 | 3 | 2012 | 589 | 0.090 |
Why?
|
| Academic Medical Centers | 3 | 2021 | 681 | 0.090 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2012 | 191 | 0.090 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 22 | 0.090 |
Why?
|
| DNA Primers | 2 | 2010 | 1496 | 0.090 |
Why?
|
| Mutation Rate | 3 | 2018 | 220 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 151 | 0.090 |
Why?
|
| Aging | 1 | 2019 | 1534 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 276 | 0.090 |
Why?
|
| Hemangiopericytoma | 1 | 2011 | 59 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 794 | 0.090 |
Why?
|
| Nuclear Envelope | 1 | 2011 | 39 | 0.090 |
Why?
|
| Mohs Surgery | 2 | 2018 | 103 | 0.090 |
Why?
|
| Niacinamide | 2 | 2012 | 428 | 0.090 |
Why?
|
| Mice, Inbred NOD | 4 | 2016 | 896 | 0.090 |
Why?
|
| Melanins | 3 | 2022 | 46 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2013 | 253 | 0.090 |
Why?
|
| Genes, Wilms Tumor | 1 | 2010 | 62 | 0.090 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 1553 | 0.090 |
Why?
|
| Withanolides | 1 | 2010 | 3 | 0.090 |
Why?
|
| Microarray Analysis | 4 | 2015 | 396 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1956 | 0.090 |
Why?
|
| Protein Binding | 1 | 2017 | 3485 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 111 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2016 | 558 | 0.090 |
Why?
|
| Cysts | 1 | 2012 | 205 | 0.090 |
Why?
|
| Hemangioma, Capillary | 1 | 2010 | 26 | 0.090 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 103 | 0.090 |
Why?
|
| Myofibroblasts | 1 | 2011 | 97 | 0.090 |
Why?
|
| Antimalarials | 1 | 2010 | 55 | 0.090 |
Why?
|
| Software | 1 | 2017 | 1355 | 0.090 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2020 | 40 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 65 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2012 | 186 | 0.090 |
Why?
|
| Phosphoproteins | 4 | 2017 | 1138 | 0.090 |
Why?
|
| Chimera | 1 | 2010 | 152 | 0.090 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2010 | 74 | 0.090 |
Why?
|
| Consensus | 3 | 2023 | 1106 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2023 | 135 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 361 | 0.090 |
Why?
|
| Mycosis Fungoides | 2 | 2018 | 341 | 0.090 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 2170 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 272 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 566 | 0.080 |
Why?
|
| Phosphatidate Phosphatase | 1 | 1999 | 17 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 210 | 0.080 |
Why?
|
| Taxoids | 1 | 2013 | 1015 | 0.080 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 1386 | 0.080 |
Why?
|
| Colon | 1 | 2013 | 659 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2009 | 29 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2016 | 1199 | 0.080 |
Why?
|
| Texas | 5 | 2020 | 6449 | 0.080 |
Why?
|
| Neurofibromin 1 | 1 | 2009 | 84 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2351 | 0.080 |
Why?
|
| Registries | 4 | 2018 | 2211 | 0.080 |
Why?
|
| Pyrophosphatases | 1 | 1999 | 49 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2012 | 437 | 0.080 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 6685 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 3240 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 35 | 0.080 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2013 | 444 | 0.080 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2008 | 2 | 0.080 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2008 | 8 | 0.080 |
Why?
|
| CREB-Binding Protein | 1 | 2009 | 98 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2009 | 60 | 0.080 |
Why?
|
| Phenylurea Compounds | 2 | 2012 | 600 | 0.080 |
Why?
|
| Phospholipase D | 1 | 1998 | 27 | 0.080 |
Why?
|
| Transcriptional Regulator ERG | 3 | 2013 | 62 | 0.080 |
Why?
|
| Mammals | 2 | 2022 | 369 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 75 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2018 | 4644 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 469 | 0.080 |
Why?
|
| Algorithms | 3 | 2018 | 3891 | 0.080 |
Why?
|
| Keratoacanthoma | 1 | 2008 | 19 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2017 | 3530 | 0.080 |
Why?
|
| Age Factors | 6 | 2018 | 5457 | 0.080 |
Why?
|
| Back | 1 | 2008 | 49 | 0.080 |
Why?
|
| Apocrine Glands | 1 | 2008 | 15 | 0.080 |
Why?
|
| Mutation, Missense | 2 | 2018 | 1192 | 0.080 |
Why?
|
| Eye Neoplasms | 1 | 2011 | 257 | 0.080 |
Why?
|
| Immunoprecipitation | 3 | 2015 | 589 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 2331 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2022 | 1458 | 0.080 |
Why?
|
| Mitotic Index | 3 | 2013 | 162 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 264 | 0.080 |
Why?
|
| Wilms Tumor | 1 | 2010 | 301 | 0.080 |
Why?
|
| Giant Cell Tumors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2007 | 22 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 1992 | 495 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2017 | 1322 | 0.070 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 907 | 0.070 |
Why?
|
| Necrosis | 3 | 2017 | 595 | 0.070 |
Why?
|
| Nevus, Blue | 1 | 2008 | 40 | 0.070 |
Why?
|
| Cellular Senescence | 2 | 2007 | 388 | 0.070 |
Why?
|
| Lung | 2 | 2023 | 3298 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2023 | 1126 | 0.070 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2008 | 45 | 0.070 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 74 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 3 | 2018 | 1109 | 0.070 |
Why?
|
| Muscle Neoplasms | 1 | 2008 | 108 | 0.070 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2007 | 4 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 1269 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 84 | 0.070 |
Why?
|
| Ritonavir | 1 | 2008 | 66 | 0.070 |
Why?
|
| Chromosomes | 2 | 2018 | 325 | 0.070 |
Why?
|
| Keratin-15 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Retinoblastoma Protein | 2 | 2023 | 339 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 1903 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 959 | 0.070 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2007 | 57 | 0.070 |
Why?
|
| Transcription Factor AP-2 | 1 | 2007 | 78 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 763 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2007 | 208 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2024 | 714 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 47 | 0.070 |
Why?
|
| Hair Follicle | 1 | 2007 | 63 | 0.070 |
Why?
|
| Thorax | 1 | 2008 | 229 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2017 | 84 | 0.070 |
Why?
|
| Rad51 Recombinase | 1 | 2007 | 125 | 0.070 |
Why?
|
| Elastic Modulus | 2 | 2019 | 35 | 0.070 |
Why?
|
| Tongue | 1 | 2007 | 86 | 0.070 |
Why?
|
| Sunlight | 1 | 2006 | 80 | 0.070 |
Why?
|
| Genes, Neoplasm | 2 | 2018 | 314 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 617 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1312 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 7044 | 0.070 |
Why?
|
| Point Mutation | 1 | 2009 | 788 | 0.070 |
Why?
|
| France | 2 | 2020 | 122 | 0.070 |
Why?
|
| Abdomen | 1 | 2008 | 347 | 0.070 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mouth Mucosa | 1 | 2007 | 224 | 0.070 |
Why?
|
| Mastectomy | 1 | 2012 | 1553 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2012 | 1005 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2013 | 1875 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 558 | 0.060 |
Why?
|
| Galectin 3 | 1 | 2006 | 131 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 3 | 2015 | 2651 | 0.060 |
Why?
|
| Flow Cytometry | 4 | 2013 | 3045 | 0.060 |
Why?
|
| Mice, Hairless | 2 | 2017 | 57 | 0.060 |
Why?
|
| Species Specificity | 2 | 2021 | 794 | 0.060 |
Why?
|
| Keratinocytes | 1 | 2006 | 244 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2009 | 902 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2006 | 1111 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 350 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 437 | 0.060 |
Why?
|
| Macrophages | 2 | 2024 | 1350 | 0.060 |
Why?
|
| Thiazoles | 1 | 2009 | 723 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2018 | 137 | 0.060 |
Why?
|
| Kidney | 3 | 2010 | 2121 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2008 | 1571 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1998 | 470 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1580 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 1998 | 2175 | 0.060 |
Why?
|
| Actins | 1 | 2008 | 602 | 0.060 |
Why?
|
| Genotype | 4 | 2018 | 4252 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 1240 | 0.060 |
Why?
|
| Esthetics | 1 | 2005 | 116 | 0.060 |
Why?
|
| Thoracic Wall | 1 | 2007 | 188 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 3844 | 0.060 |
Why?
|
| Valosin Containing Protein | 1 | 2024 | 14 | 0.060 |
Why?
|
| Cathepsin K | 1 | 2024 | 15 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 310 | 0.060 |
Why?
|
| Incidence | 4 | 2020 | 5824 | 0.060 |
Why?
|
| Peptides | 1 | 2010 | 1504 | 0.060 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2115 | 0.060 |
Why?
|
| Hospitals, High-Volume | 1 | 2024 | 76 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2007 | 743 | 0.060 |
Why?
|
| Axilla | 1 | 2007 | 939 | 0.060 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2023 | 23 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 575 | 0.060 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2023 | 115 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2017 | 823 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 165 | 0.050 |
Why?
|
| Epigenomics | 1 | 2024 | 273 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2018 | 51 | 0.050 |
Why?
|
| Critical Care | 1 | 2009 | 796 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2024 | 201 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 205 | 0.050 |
Why?
|
| Piperidines | 1 | 2008 | 1100 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Indazoles | 1 | 2024 | 310 | 0.050 |
Why?
|
| PUVA Therapy | 1 | 2012 | 34 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2024 | 339 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 3046 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 518 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2024 | 267 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 719 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 1993 | 185 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2024 | 315 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 75 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1894 | 0.050 |
Why?
|
| Cross Reactions | 2 | 2013 | 263 | 0.050 |
Why?
|
| Placenta Growth Factor | 1 | 2022 | 26 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 1461 | 0.050 |
Why?
|
| Catalysis | 2 | 2015 | 245 | 0.050 |
Why?
|
| Langer-Giedion Syndrome | 1 | 2022 | 21 | 0.050 |
Why?
|
| Loss of Heterozygosity | 2 | 2018 | 623 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2018 | 1246 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2024 | 247 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 46 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 4567 | 0.050 |
Why?
|
| Hyaluronan Receptors | 1 | 2003 | 248 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2004 | 280 | 0.050 |
Why?
|
| Laminin | 1 | 2022 | 210 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2018 | 2315 | 0.050 |
Why?
|
| Phototherapy | 1 | 2012 | 83 | 0.050 |
Why?
|
| Mitochondria | 1 | 2009 | 1297 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 1121 | 0.050 |
Why?
|
| Protein Array Analysis | 2 | 2016 | 503 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2003 | 293 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 4223 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2022 | 306 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2024 | 363 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4795 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2012 | 188 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2024 | 524 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2022 | 255 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2007 | 761 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2024 | 383 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2018 | 1179 | 0.050 |
Why?
|
| Neural Crest | 1 | 2021 | 85 | 0.050 |
Why?
|
| Foot | 1 | 2021 | 94 | 0.050 |
Why?
|
| Nose | 1 | 2022 | 141 | 0.050 |
Why?
|
| Dasatinib | 2 | 2018 | 881 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2021 | 132 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2012 | 322 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1525 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2012 | 109 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2024 | 878 | 0.050 |
Why?
|
| Radiation | 1 | 2020 | 19 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 273 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 929 | 0.050 |
Why?
|
| Liver | 3 | 2020 | 3086 | 0.040 |
Why?
|
| Immunogenetic Phenomena | 1 | 2020 | 9 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Esophagoplasty | 1 | 2000 | 28 | 0.040 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 80 | 0.040 |
Why?
|
| Hand | 1 | 2021 | 175 | 0.040 |
Why?
|
| Genes, Reporter | 3 | 2007 | 820 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 116 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2024 | 779 | 0.040 |
Why?
|
| Burns, Chemical | 1 | 2000 | 32 | 0.040 |
Why?
|
| Europe | 2 | 2012 | 658 | 0.040 |
Why?
|
| Genome | 2 | 2017 | 690 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2020 | 197 | 0.040 |
Why?
|
| Mediastinum | 1 | 2021 | 276 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 294 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 257 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2019 | 76 | 0.040 |
Why?
|
| Gelatin | 1 | 2019 | 43 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 1160 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 1020 | 0.040 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 63 | 0.040 |
Why?
|
| Polyesters | 1 | 2019 | 68 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 112 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 1054 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 953 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2020 | 163 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 325 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 45 | 0.040 |
Why?
|
| Androgens | 1 | 2022 | 506 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 965 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2400 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 119 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2020 | 259 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1456 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 160 | 0.040 |
Why?
|
| Integrin beta Chains | 1 | 2018 | 37 | 0.040 |
Why?
|
| Fucosyltransferases | 1 | 2018 | 78 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2000 | 196 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2018 | 50 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 1503 | 0.040 |
Why?
|
| Th1-Th2 Balance | 1 | 2018 | 13 | 0.040 |
Why?
|
| Prevalence | 2 | 2021 | 3404 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 112 | 0.040 |
Why?
|
| Entropy | 1 | 2018 | 36 | 0.040 |
Why?
|
| Equipment Design | 2 | 2012 | 1197 | 0.040 |
Why?
|
| DNA | 2 | 2023 | 3050 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 457 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 1604 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 145 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 672 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2018 | 104 | 0.040 |
Why?
|
| Platelet Count | 1 | 1999 | 492 | 0.040 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2008 | 84 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 313 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 861 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 1063 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 367 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1999 | 735 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2021 | 668 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 530 | 0.040 |
Why?
|
| Pathology, Surgical | 1 | 2018 | 78 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2022 | 799 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 235 | 0.040 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 84 | 0.040 |
Why?
|
| Biological Evolution | 1 | 1989 | 290 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 4000 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 98 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2013 | 1726 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5056 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2016 | 6224 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 224 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2017 | 120 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 722 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 689 | 0.040 |
Why?
|
| Stomach | 1 | 2000 | 402 | 0.040 |
Why?
|
| Leukocytes | 1 | 1999 | 421 | 0.040 |
Why?
|
| Molecular Motor Proteins | 1 | 2016 | 35 | 0.040 |
Why?
|
| Immune System | 1 | 2018 | 275 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 153 | 0.030 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 168 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 323 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 178 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2016 | 72 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 46 | 0.030 |
Why?
|
| Copper-transporting ATPases | 1 | 2016 | 44 | 0.030 |
Why?
|
| Esophagus | 1 | 2000 | 563 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 151 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2014 | 2828 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2017 | 229 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 1341 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2017 | 299 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 223 | 0.030 |
Why?
|
| Cell Line | 4 | 2015 | 5338 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 737 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2018 | 324 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2016 | 122 | 0.030 |
Why?
|
| Metagenome | 1 | 2017 | 193 | 0.030 |
Why?
|
| Allografts | 1 | 2018 | 686 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 266 | 0.030 |
Why?
|
| Documentation | 1 | 2018 | 213 | 0.030 |
Why?
|
| Netherlands | 1 | 2016 | 90 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 143 | 0.030 |
Why?
|
| DNA Damage | 1 | 2024 | 1989 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 355 | 0.030 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Remission Induction | 2 | 2015 | 3656 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 174 | 0.030 |
Why?
|
| Cadherins | 2 | 2010 | 657 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1184 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 737 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 5923 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3077 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 59 | 0.030 |
Why?
|
| Neoplasms, Experimental | 3 | 2012 | 784 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2011 | 1655 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 293 | 0.030 |
Why?
|
| Defecation | 1 | 2015 | 57 | 0.030 |
Why?
|
| California | 1 | 2016 | 212 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 274 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 741 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5574 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 374 | 0.030 |
Why?
|
| Video Recording | 1 | 2017 | 281 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 170 | 0.030 |
Why?
|
| HIV Infections | 1 | 2008 | 2154 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 2015 | 24 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2015 | 98 | 0.030 |
Why?
|
| Luciferases | 2 | 2006 | 460 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2023 | 2232 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 295 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2015 | 162 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 344 | 0.030 |
Why?
|
| Quality of Life | 2 | 2022 | 4761 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1483 | 0.030 |
Why?
|
| Mitosis | 1 | 2017 | 681 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1218 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1437 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 1 | 1995 | 90 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1477 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 743 | 0.030 |
Why?
|
| Neutrophils | 1 | 1999 | 873 | 0.030 |
Why?
|
| Sclerosing Solutions | 1 | 1994 | 27 | 0.030 |
Why?
|
| Microscopy | 1 | 2015 | 189 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2018 | 654 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2015 | 144 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 206 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 656 | 0.030 |
Why?
|
| Quinolines | 1 | 2017 | 402 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 3156 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1996 | 230 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 427 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 840 | 0.030 |
Why?
|
| Myocarditis | 1 | 1996 | 181 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 223 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 859 | 0.030 |
Why?
|
| Lysine | 1 | 2016 | 426 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 339 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1137 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 625 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 4019 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 669 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1369 | 0.030 |
Why?
|
| Caproates | 1 | 2013 | 10 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 307 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2013 | 5694 | 0.030 |
Why?
|
| Pyrazines | 1 | 2016 | 510 | 0.030 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 417 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2018 | 1049 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2012 | 1696 | 0.030 |
Why?
|
| Hardness Tests | 1 | 2012 | 4 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 593 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2013 | 336 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2014 | 294 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2018 | 1474 | 0.030 |
Why?
|
| Adenosine | 1 | 2015 | 294 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 2013 | 87 | 0.030 |
Why?
|
| Air | 1 | 2012 | 65 | 0.030 |
Why?
|
| Lactones | 1 | 2013 | 94 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 243 | 0.030 |
Why?
|
| Emergencies | 1 | 1994 | 224 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 187 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 562 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1557 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.030 |
Why?
|
| Fixatives | 1 | 2012 | 31 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 496 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2012 | 193 | 0.030 |
Why?
|
| United Kingdom | 1 | 2012 | 287 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 613 | 0.020 |
Why?
|
| PAX3 Transcription Factor | 1 | 2011 | 36 | 0.020 |
Why?
|
| Pyridazines | 1 | 2015 | 324 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1991 | 46 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 154 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 184 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2012 | 98 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2012 | 82 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 2431 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2018 | 1567 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 433 | 0.020 |
Why?
|
| Azepines | 1 | 2012 | 134 | 0.020 |
Why?
|
| Risk | 1 | 2016 | 1939 | 0.020 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 1472 | 0.020 |
Why?
|
| Hepatectomy | 1 | 1998 | 1015 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 149 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1991 | 112 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2011 | 162 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 1992 | 174 | 0.020 |
Why?
|
| Stem Cells | 1 | 2018 | 1216 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 796 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1248 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 209 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 225 | 0.020 |
Why?
|
| Brain | 2 | 2014 | 4208 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2011 | 176 | 0.020 |
Why?
|
| Rabbits | 1 | 2012 | 1028 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 153 | 0.020 |
Why?
|
| Treatment Failure | 1 | 1994 | 1430 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8699 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 232 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2010 | 257 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2015 | 1060 | 0.020 |
Why?
|
| Perilipin-2 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2010 | 120 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 239 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2123 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 2010 | 82 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2904 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 84 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2011 | 225 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4492 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Histiocytes | 1 | 2010 | 94 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2011 | 398 | 0.020 |
Why?
|
| Siblings | 1 | 2011 | 319 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 495 | 0.020 |
Why?
|
| CA-125 Antigen | 1 | 2011 | 229 | 0.020 |
Why?
|
| Dolichol Phosphates | 1 | 1999 | 2 | 0.020 |
Why?
|
| Surgeons | 1 | 2016 | 491 | 0.020 |
Why?
|
| Giant Cells | 1 | 2010 | 73 | 0.020 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 1999 | 5 | 0.020 |
Why?
|
| Lymphatic Vessel Tumors | 1 | 2009 | 3 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 438 | 0.020 |
Why?
|
| Leg Ulcer | 1 | 2009 | 17 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 655 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2027 | 0.020 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2009 | 33 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 2345 | 0.020 |
Why?
|
| Sesquiterpenes | 1 | 1999 | 70 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2010 | 295 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2197 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 909 | 0.020 |
Why?
|
| Sarcoma, Experimental | 1 | 2009 | 68 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2009 | 95 | 0.020 |
Why?
|
| Furans | 1 | 2009 | 102 | 0.020 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 1998 | 26 | 0.020 |
Why?
|
| Magnesium | 1 | 1999 | 170 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2009 | 79 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2009 | 146 | 0.020 |
Why?
|
| Anilides | 1 | 2011 | 295 | 0.020 |
Why?
|
| Mosaicism | 1 | 2010 | 293 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2580 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1754 | 0.020 |
Why?
|
| Drug Design | 1 | 2010 | 372 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 153 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 1252 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2008 | 94 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1998 | 128 | 0.020 |
Why?
|
| 12E7 Antigen | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2008 | 152 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 183 | 0.020 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2008 | 40 | 0.020 |
Why?
|
| Lopinavir | 1 | 2008 | 10 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2008 | 157 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 691 | 0.020 |
Why?
|
| Myosins | 1 | 2008 | 97 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 685 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2008 | 183 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2008 | 190 | 0.020 |
Why?
|
| Sebaceous Glands | 1 | 2007 | 12 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 7265 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 692 | 0.020 |
Why?
|
| Merkel Cells | 1 | 2007 | 7 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2184 | 0.020 |
Why?
|
| Ankle | 1 | 2007 | 37 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2007 | 43 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2010 | 521 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2007 | 83 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 298 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2007 | 128 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 967 | 0.020 |
Why?
|
| Papilloma | 1 | 2007 | 86 | 0.020 |
Why?
|
| Chromogranins | 1 | 2007 | 86 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 690 | 0.020 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2008 | 166 | 0.020 |
Why?
|
| Living Donors | 1 | 2007 | 175 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2007 | 88 | 0.020 |
Why?
|
| Response Elements | 1 | 2007 | 192 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2011 | 1275 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 1840 | 0.020 |
Why?
|
| Ethanol | 1 | 1998 | 272 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1993 | 1933 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 1286 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 101 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 3028 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 823 | 0.020 |
Why?
|
| Methylcellulose | 2 | 1963 | 10 | 0.020 |
Why?
|
| Cytoplasm | 2 | 2006 | 702 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 1810 | 0.020 |
Why?
|
| SEER Program | 1 | 2009 | 1047 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 225 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 494 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 82 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2006 | 498 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 1741 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3707 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 1082 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2012 | 1716 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 1986 | 0.010 |
Why?
|
| Fibrosis | 1 | 2007 | 733 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 746 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2008 | 481 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2006 | 909 | 0.010 |
Why?
|
| Intestines | 1 | 2008 | 736 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 938 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5257 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2006 | 1075 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1049 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 2394 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 2025 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2003 | 176 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 1690 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1569 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 1654 | 0.010 |
Why?
|
| Caustics | 1 | 2000 | 6 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 1432 | 0.010 |
Why?
|
| Cricetinae | 2 | 1989 | 769 | 0.010 |
Why?
|
| Esophageal Stenosis | 1 | 2000 | 91 | 0.010 |
Why?
|
| Stomach Diseases | 1 | 2000 | 72 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2600 | 0.010 |
Why?
|
| Endometrium | 1 | 2003 | 457 | 0.010 |
Why?
|
| Macropodidae | 1 | 1989 | 13 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1963 | 1067 | 0.010 |
Why?
|
| Cricetulus | 1 | 1989 | 214 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2003 | 499 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 2657 | 0.010 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1998 | 75 | 0.010 |
Why?
|
| HeLa Cells | 2 | 1989 | 1685 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 8130 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1989 | 895 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4372 | 0.010 |
Why?
|
| Azathioprine | 1 | 1996 | 73 | 0.010 |
Why?
|
| Anura | 1 | 1974 | 18 | 0.010 |
Why?
|
| Rats | 2 | 1989 | 6441 | 0.010 |
Why?
|
| DNA Viruses | 1 | 1974 | 45 | 0.010 |
Why?
|
| Prednisone | 1 | 1996 | 1034 | 0.010 |
Why?
|
| Temperature | 1 | 1974 | 538 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1996 | 564 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1978 | 882 | 0.010 |
Why?
|
| Myocardium | 1 | 1996 | 1232 | 0.010 |
Why?
|
| Echocardiography | 1 | 1996 | 1228 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 1963 | 114 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1963 | 299 | 0.000 |
Why?
|
| Urban Population | 1 | 1978 | 280 | 0.000 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1974 | 14 | 0.000 |
Why?
|
| Viral Plaque Assay | 1 | 1974 | 53 | 0.000 |
Why?
|
| Crystallography | 1 | 1974 | 57 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1974 | 707 | 0.000 |
Why?
|
| Mass Screening | 1 | 1978 | 1552 | 0.000 |
Why?
|